https://www.targetedonc.com/view/fda-approves-liso-cel-car-t-cell-therapy-for-relapsed-refractory-large-b-cell-lymphoma
The above link is to an announcement of an FDA approval of a CarT drug after a phase 1 trial. Check out the percentage of adverse events (79%), leading to 7 deaths. 53% CR. But still better for the patient cohort than not using this treatment. CarT approvals are moving much faster than other cancer drug discovery.
Also remember that over 40% of the CHM share register is held in Escrow for the next 23 months. So not a lot of free float if someone wants a large purchase.
CLTX-CAR T is a game changer, page-5
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
